VBC’s Payer Problem: Why Vertical Integration Fails

The convergence of value-based care (VBC) models and technological innovation, particularly in AI, has reshaped the healthcare investment landscape. Yet, a recurring pattern emerges for VBC-centric companies attempting to integrate deeply into the insurance payer space: a struggle for sustained viability. This analysis delves into why this expansion often culminates in divestiture or significant restructuring, using NeueHealth, Clover Health, and Oscar Health as illustrative case studies, and emphasizing the critical importance of scope discipline for durable funding trajectories.

The Allure and Peril of Vertical Integration: NeueHealth’s Failed Pivot

The promise of VBC is clear: incentivize outcomes, not volume. For many, integrating health plan functions seemed a logical extension, offering greater control over the patient journey and cost management. NeueHealth, a subsidiary of Bright Health Group, exemplified this ambition. Initially built around a network of primary care clinics and a technology platform designed to support VBC arrangements, NeueHealth sought to leverage its clinical infrastructure by operating its own health plans. The rationale was compelling on paper: by aligning incentives across care delivery and insurance, they could theoretically optimize costs and improve patient health more effectively than traditional models. However, the reality proved far more complex. Operating a health plan entails a distinct set of operational, regulatory, and financial challenges that differ significantly from managing provider networks. Insurance is a capital-intensive business, requiring substantial reserves, sophisticated actuarial capabilities, and intricate regulatory navigation. NeueHealth’s attempt to pivot into this dual role ultimately proved unsustainable. The company’s trajectory culminated in a going-private transaction on October 2, 2025, effectively marking a failed-pivot from its ambitious vertical integration strategy. This outcome underscores a critical lesson: the competencies required to excel as a VBC provider are not automatically transferable to the insurance domain. The capital demands alone, coupled with the inherent volatility of insurance risk, can quickly overwhelm even well-funded enterprises.

Clover Health and the Capital Sink of Insurance Operations

Clover Health presents another salient example of a VBC company that ventured into the insurance sector with significant fanfare, particularly around its AI-driven approach to care management. The company positioned its “Clover Assistant” as a core differentiator, using AI to provide data-driven insights to primary care physicians at the point of care, ostensibly improving outcomes and reducing costs for its Medicare Advantage members. While the clinical outcomes and payer contracts are often cited as key indicators of funding durability (DP-35), Clover Health’s journey highlights that even with a compelling technological narrative and initial funding success, the complexities of being a full-stack insurer can dilute focus and drain capital. Clover Health competes with established VBC players like agilon health, which primarily focuses on enabling physician groups to succeed in VBC arrangements, rather than directly underwriting insurance risk. This distinction is crucial. While agilon health provides the technological and operational scaffolding for VBC, it largely avoids the direct financial exposure of being an insurer. Clover Health, by contrast, assumed both roles. The capital requirements for scaling an insurance business, particularly in the highly regulated and competitive Medicare Advantage market, are immense. Despite significant venture capital infusions and a public market debut, Clover Health has recently demonstrated a notable turnaround. The company reported its first-ever positive GAAP net income of $27.3 million in Q1 2026, with total revenues rising to $749.2 million, driven by increased Medicare Advantage membership. Management expects to achieve its first full year of GAAP net income profitability in 2026. This recent performance suggests that while the operational and financial burden of insurance can be challenging, innovative AI platforms, when coupled with strategic execution, can lead to sustainable profitability and demonstrate the long-term funding durability that investors seek (DP-41). The market often penalizes companies attempting to master two inherently different, capital-intensive businesses simultaneously.

Oscar Health: A Digital Native’s Struggle for Scope Discipline

Oscar Health entered the market with a strong digital-first narrative, aiming to disrupt traditional health insurance through a superior user experience and data-driven insights. While not primarily a VBC provider in the same vein as NeueHealth’s clinic-centric model, Oscar Health’s ambition to integrate technology with insurance operations offers parallel insights into the challenges of scope expansion. Their initial strategy focused on leveraging technology to simplify insurance for consumers and providers, including AI-powered navigation and personalized care guidance. However, like NeueHealth and Clover Health, Oscar Health grappled with the inherent difficulties of the insurance business. The pursuit of rapid growth in a highly regulated and competitive industry, coupled with the significant investment required to build and maintain its technological infrastructure, led to substantial losses. However, Oscar Health has recently achieved a significant financial turnaround, reporting a net income of $679 million in Q1 2026, with total revenue reaching $4.6 billion. The company also improved its medical loss ratio to 70.5% and reaffirmed its guidance for meaningful profitability in 2026. This demonstrates that while the path to profitability can be challenging, strategic shifts and improved operational efficiency can lead to strong financial performance. Oscar Health’s journey underscores that even a strong technological foundation and a clear vision for digital transformation can eventually overcome the financial realities of underwriting health risk. The market’s assessment of funding durability is often tied to demonstrated operational efficiency and a clear path to profitability, which can be obscured when a company attempts to simultaneously innovate in technology and navigate the complexities of insurance.

The Criticality of Scope Discipline for Funding Durability

The experiences of NeueHealth, Clover Health, and Oscar Health converge on a central theme: the critical importance of scope discipline. For VCs and growth equity investors, evaluating healthcare AI venture capital opportunities increasingly involves scrutinizing whether companies are attempting to conquer too many fronts simultaneously. The “top venture capital firms healthcare AI” landscape is evolving, favoring models that demonstrate focused expertise and a clear understanding of their core value proposition. Companies that maintain a tighter focus, such as those providing AI-powered tools for VBC enablement or specialized care delivery, often exhibit more predictable and durable funding trajectories. They can demonstrate clearer clinical outcomes and more straightforward payer contracts (DP-35) because their offerings are distinct and measurable within a defined operational scope. When a company expands into underwriting insurance, it introduces a layer of financial risk and regulatory complexity that can overshadow its core technological or clinical innovations. The digital health funding rounds tracker reveals that sustained investment often correlates with companies that can articulate and execute a precise strategy, rather than those attempting to be all things to all stakeholders.

Key Takeaway: Focus Drives Funding Durability

The narrative emerging from the struggles of NeueHealth, Clover Health, and Oscar Health is a cautionary tale for VBC companies contemplating deep integration into the insurance payer domain. While the ambition to control more of the healthcare value chain is understandable, the distinct operational, regulatory, and financial demands of running an insurance enterprise can quickly dilute focus and strain capital resources. For investors, the lesson is clear: examine the scope. Companies that demonstrate a disciplined approach, focusing on their core VBC or AI-enabled service delivery, are more likely to achieve the consistent clinical outcomes and secure the stable payer contracts that underpin long-term funding durability (DP-41). The most successful AI health company funding in 2026 and beyond will likely flow to those who understand that mastering one complex domain is often more profitable and sustainable than attempting to conquer two. Analysis of capital requirements for health insurance startups This is not to say innovation should be stifled, but rather that strategic expansion must be meticulously planned and executed, with a clear understanding of the distinct challenges each domain presents. Report on VBC provider vs. payer financial models Regulatory compliance burdens for health insurance providers